Halozyme Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Halozyme Therapeutics generated cash of $388,571,000, which is more than the previous year. Cash used in financing activities reached the amount of -$407,987,000 last year. Net change in cash is therefore -$116,325,000.
Cash Flow
| 2014 | -47.51M | -32.95M | 114.50M |
|---|---|---|---|
| 2015 | -37.08M | 5.88M | 13.09M |
| 2016 | -50.38M | -76.76M | 150.62M |
| 2017 | 134.05M | -163.73M | 131.65M |
| 2018 | -49.5M | 2.49M | -63.79M |
| 2019 | -85.42M | -5.54M | 153.21M |
| 2020 | 55.45M | 78.35M | -106.28M |
| 2021 | 299.44M | -406.28M | 77.86M |
| 2022 | 240.11M | -487.00M | 362.37M |
| 2023 | 388.57M | -96.90M | -407.98M |
HALO Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 234.69M | 119.21M | 148.20M | 120.67M | 58.43M | 169.24M | 67.26M | 43.29M | 61.38M | 27.35M |
Operating activities | ||||||||||
Net income | 281.59M | 202.12M | 402.71M | 129.08M | -72.24M | -80.33M | 62.97M | -103.02M | -32.23M | -68.37M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 84.85M | 49.64M | 2.99M | 3.28M | 4.06M | 2.38M | 2.16M | 2.41M | 1.67M | 1.76M |
Stock-based compensation expense | 36.62M | 24.39M | 20.82M | 17.20M | 34.77M | 0 | 30.67M | 25.58M | 20.83M | 15.27M |
| Deferred income tax benefit | 36.62M | 24.39M | 20.82M | 17.20M | 34.77M | 0 | 30.67M | 25.58M | 20.83M | 15.27M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -3.33M | -83.94M | 6.75M | -38.28M | -29.43M | 11.61M | -6.45M | 16.73M | -23.26M | -52K |
Inventories | -26.88M | -17.48M | 7.37M | -31.38M | -6.73M | -17.48M | 9.47M | -5.13M | -3.08M | -236K |
Accounts payable | -12.54M | 24.53M | 1.16M | -41.20M | 4.63M | -278.48M | 15.62M | -244K | 13.86M | -816K |
Cash generated by operating activities | 388.57M | 240.11M | 299.44M | 55.45M | -85.42M | -49.5M | 134.05M | -50.38M | -37.08M | -47.51M |
Investing activities | ||||||||||
Purchases Of Investments | -292.91M | -255.20M | -652.51M | -226.18M | -389.75M | -311.11M | -398.18M | -155.41M | -71.48M | -88.88M |
Investments In Property Plant And Equipment | -15.29M | -4.81M | -1.45M | -2.50M | -4.04M | -4.66M | -1.35M | -3.13M | -2.36M | -1.36M |
Acquisitions Net | 0 | -999.12M | 404.83M | 1.07M | 1.50M | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -96.90M | -487.00M | -406.28M | 78.35M | -5.54M | 2.49M | -163.73M | -76.76M | 5.88M | -32.95M |
Financing activities | ||||||||||
Common Stock Issued | 7.87M | 14.05M | 12.53M | 63.39M | 14.22M | 13.71M | 134.87M | 1.86M | 13.09M | 107.71M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -402.38M | -200.00M | -350.05M | -150.11M | -199.99M | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -13.48M | 624.54M | -369.06M | -19.56M | 339.26M | -77.51M | -15.99M | -54.25M | 0 | 0 |
Cash used in financing activities | -407.98M | 362.37M | 77.86M | -106.28M | 153.21M | -63.79M | 131.65M | 150.62M | 13.09M | 114.50M |
Net Change In Cash | -116.32M | 115.47M | -28.98M | 27.52M | 62.24M | -110.80M | 101.97M | 23.47M | -18.09M | 34.03M |
Cash at end of period | 118.37M | 234.69M | 119.21M | 148.20M | 120.67M | 58.43M | 169.24M | 66.76M | 43.29M | 61.38M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |